Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) will report its second quarter 2026 financial results before the open of U.S. financial markets on Thursday, August 6, 2026. The Chicago-headquartered biopharmaceutical company, which develops and commercializes innovative products across various therapies, scheduled the announcement to provide investors with an update on its operational and financial trajectory. The results will cover the performance of its three commercially available products: Recorlev for endogenous Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis.

Management will host a conference call and webcast at 8:30 a.m. Eastern Time on August 6, 2026, to discuss the quarter’s outcomes. Interested parties are advised to pre-register for the call via the company’s Investor Relations website or through the provided registration link. Attendees are recommended to register 15 minutes prior to the scheduled webcast start time to ensure seamless access.

The webcast and replay will be accessible on Xeris Biopharma’s investor relations website following the event. This disclosure serves as the primary mechanism for stakeholders to engage with executive leadership regarding the company’s latest fiscal performance and strategic updates.

Key Dates and Access Details

Company Overview and Pipeline

Xeris Biopharma Holdings continues to advance its pipeline of development programs alongside its commercial portfolio. The company highlighted XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as a key component of its development strategy. Additionally, Xeris is leveraging its proprietary technology platforms, XeriSol and XeriJect, to support multiple early-stage programs for its partners.

Investor inquiries can be directed to Allison Wey, Senior Vice President of Investor Relations and Corporate Communications, at awey@xerispharma.com . For further information, investors may visit www.xerispharma.com or follow the company on social media platforms including X, LinkedIn, and Instagram.

Xeris Biopharma Holdings, Inc. granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees on July 1, 2026. The grants were issued by the Compensation Committee of Xeris’ Board of Directors under the company's Inducement Equity Plan. This plan is used exclusively for equity awards to individuals as an inducement material to their entry into employment with Xeris or its subsidiaries, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The restricted stock units will vest over a period of three years in equal annual installments. Vesting is contingent upon the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of the Inducement Equity Plan and the applicable award agreements.

Grant Details

About Xeris Biopharma Holdings

Xeris is a biopharmaceutical company focused on developing and commercializing innovative products across various therapies. The company has three commercially available products: Recorlev® for endogenous Cushing’s syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis. Xeris also has a pipeline of development programs, including XP-8121 for hypothyroidism, and early-stage programs leveraging its XeriSol® and XeriJect® technology platforms.